A COVID-19 vaccine candidate that underwent extensive preclinical testing at the University of Alabama at Birmingham this spring and summer shows potent preclinical immune responses—including several that distinguish it from other COVID-19 vaccine approaches—according to a preprint deposited in the BioRxiv repository this week. Partial preclinical results had been announced in July and August by